# General Inception

> General Inception is a VC fund backing Biotechnology and Health Care. See 9 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 9
- Last investment: Mar 2026
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/generalinception/
- Website: https://generalinception.com/

General Inception is an institutional co-founder for science-based companies bringing specialized expertise, operational resources and capital to innovation.

## Contacts

5 contacts available for General Inception. Shizune tracks 6 team members at General Inception. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/general-inception?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 7 | 78% |
| Health Care | 3 | 33% |
| Life Science | 3 | 33% |
| Medical | 1 | 11% |
| Chemical | 1 | 11% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 5 | 56% |
| Pre-Seed | 4 | 44% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 44% |
| United Kingdom | 2 | 22% |
| Spain | 1 | 11% |
| France | 1 | 11% |
| Belgium | 1 | 11% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Francois Valencony | Chief Investment & Business Officer | 16 | https://shizune.co/investors/profile/francois-valencony |
| Jeff Rieger | Fractional Executive | 0 | https://shizune.co/investors/profile/jeff-rieger |
| Paul Conley | CEO & Co-founder | 22 | https://shizune.co/investors/profile/dr-paul-conley |
| Soumya Ray | Fraction Executive, Advisor and Company Builder | 0 | https://shizune.co/investors/profile/soumya-ray-6e41 |
| Venkat Reddy | CSO | 0 | https://shizune.co/investors/profile/venkat-reddy-ebe8 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Surf Therapeutics | Surf Therapeutics is a clinical-stage firm leading the development of non-invasive ultrasound neuromodulation technology to modify immune-related pathways. | $6M | Seed | Mar 17, 2026 |  |
| Planet Smart | Planet Smart is a London-based deep tech startup creating smarter biomaterials for a better planet. Its flagship innovation, PlanetSorb™, is the world’s first naturally biodegradable, high-performance superabsorbent polymer designed to replace fossil-based plastics in hygiene, agriculture, packaging and mining waste products. Founded by Dr GeraldMarin and Maurice Rüttimann, Planet Smart’s mission is to eliminate microplastics from everyday life and prove that sustainable design can outperform the status quo. | $1M | Pre-Seed | Nov 18, 2025 |  |
| Biocellis | Biocellis offer new generation diagnostic solutions for individual healthcare. |  | Seed | Jun 18, 2025 |  |
| Tavira Therapeutics | Tavira Therapeutics develops an advanced platform that enhances gene delivery of AAV (adeno-associated virus). The company's approach is to equip AAV vectors with specific molecules that allow for more targeted and safer gene therapies, representing a significant advancement in the field. Founded as a spin-off from KU Leuven and Trellis,Tavira is leveraging groundbreaking research to develop modular AAV capsid technologies to improve gene therapy treatments. | $1.1M | Pre-Seed | Oct 01, 2024 |  |
| Pharmacelera | Pharmacelera is a company that applies accurate Quantum-Mechanics (QM) algorithms, Machine Learning (ML) and High-Performance Computing (HPC) to mine an unexploited chemical space and propose molecular candidates that have higher chances to become a drug. The patented computational technology derives from more than 25 years of research at theUniversity of Barcelona and it has been validated in scientific peer-reviewed publications and benchmarking studies performed by our users and customers. | $1.7M | Seed | Apr 01, 2023 |  |
| Constructive Bio | Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things. | $15M | Seed | Aug 15, 2022 |  |
| Alida Biosciences | Alida Biosciences is a biotech company creating RNA analysis tools to improve human health. The company was founded in 2020 and is headquartered in San Diego, CA. | $510K | Pre-Seed | Jul 02, 2021 |  |
| Sestina Bio | At Sestina Bio, LLC their mission is to create a technology centric, R&D platform that will tackle some of the largest challenges of the 21st century and provide cutting edge solutions to sustainably feed, clothe, and keep healthy the growing world population. their approach is to integrate, and where needed create, the most innovative andnovel advances in synthetic biology, data sciences, and bio-analytical systems. |  | Seed | Oct 14, 2020 |  |
| Switchback Systems | Switchback Systems is an early-stage startup engaged in the rapid development of a highly scalable DNA synthesis platform. It focuses on dramatic minimization of time, cost, and waste, for utilization in a wide range of nucleic acid applications. The company was founded in 2019 by Mary Noe. | $400K | Pre-Seed | May 08, 2020 |  |

9 of 9 investments shown.

## Co-investors
- [OMX Ventures](https://shizune.co/investors/profile/omx-ventures) — VC Fund, 2 deals together
- [Vertical Venture Partners](https://shizune.co/investors/profile/vertical-venture-partners) — VC Fund, 2 deals together
- [Ahren Innovation Capital](https://shizune.co/investors/profile/ahren-innovation-capital) — VC Fund, 1 deal together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 1 deal together
- [Elderberry Ventures](https://shizune.co/investors/profile/elderberry-ventures) — VC Fund, 1 deal together
- [Evoce Capital](https://shizune.co/investors/profile/evoce-capital) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [ENISA](https://shizune.co/investors/profile/enisa-2) — VC Fund
- [Inveready](https://shizune.co/investors/profile/inveready-technology-investment-group) — VC Fund
- [Angels Capital](https://shizune.co/investors/profile/angels-capital) — VC Fund

## Featured in investor lists
- [Life Science Investors in Spain](https://shizune.co/investors/life-science-investors-spain)

## FAQ

### What does General Inception invest in?

General Inception invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Pre-Seed stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact General Inception?

Public channels for General Inception include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at General Inception?

The team at General Inception includes Francois Valencony (Chief Investment & Business Officer), Jeff Rieger (Fractional Executive) and Paul Conley (CEO & Co-founder), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co